FI3386546T3 - Yhdistelmä metastaattisen syövän tehokkaaseen hoitoon potilailla - Google Patents
Yhdistelmä metastaattisen syövän tehokkaaseen hoitoon potilailla Download PDFInfo
- Publication number
- FI3386546T3 FI3386546T3 FIEP16820404.8T FI16820404T FI3386546T3 FI 3386546 T3 FI3386546 T3 FI 3386546T3 FI 16820404 T FI16820404 T FI 16820404T FI 3386546 T3 FI3386546 T3 FI 3386546T3
- Authority
- FI
- Finland
- Prior art keywords
- hydroxocobalamin
- nitrosourea
- chloroethyl
- bis
- ascorbic acid
- Prior art date
Links
- 208000037819 metastatic cancer Diseases 0.000 title claims 12
- 208000011575 metastatic malignant neoplasm Diseases 0.000 title claims 12
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 claims 64
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 56
- 229960001103 hydroxocobalamin Drugs 0.000 claims 32
- 235000004867 hydroxocobalamin Nutrition 0.000 claims 32
- 239000011704 hydroxocobalamin Substances 0.000 claims 32
- 238000000034 method Methods 0.000 claims 29
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 28
- 229960005070 ascorbic acid Drugs 0.000 claims 28
- 235000010323 ascorbic acid Nutrition 0.000 claims 28
- 239000011668 ascorbic acid Substances 0.000 claims 28
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 25
- 229960001924 melphalan Drugs 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
- 102100034484 DNA repair protein RAD51 homolog 3 Human genes 0.000 claims 4
- 102100034553 Fanconi anemia group J protein Human genes 0.000 claims 4
- 101001132271 Homo sapiens DNA repair protein RAD51 homolog 3 Proteins 0.000 claims 4
- 101000848171 Homo sapiens Fanconi anemia group J protein Proteins 0.000 claims 4
- 108700020462 BRCA2 Proteins 0.000 claims 3
- 102000052609 BRCA2 Human genes 0.000 claims 3
- 101150008921 Brca2 gene Proteins 0.000 claims 3
- 102100025401 Breast cancer type 1 susceptibility protein Human genes 0.000 claims 3
- 102100029094 DNA repair endonuclease XPF Human genes 0.000 claims 3
- 101000702606 Homo sapiens Structure-specific endonuclease subunit SLX4 Proteins 0.000 claims 3
- 101000837581 Homo sapiens Ubiquitin-conjugating enzyme E2 T Proteins 0.000 claims 3
- 102100031003 Structure-specific endonuclease subunit SLX4 Human genes 0.000 claims 3
- 102100028705 Ubiquitin-conjugating enzyme E2 T Human genes 0.000 claims 3
- 210000004602 germ cell Anatomy 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 108700020463 BRCA1 Proteins 0.000 claims 2
- 101150072950 BRCA1 gene Proteins 0.000 claims 2
- 102100022928 DNA repair protein RAD51 homolog 1 Human genes 0.000 claims 2
- 108010067741 Fanconi Anemia Complementation Group N protein Proteins 0.000 claims 2
- 102000016627 Fanconi Anemia Complementation Group N protein Human genes 0.000 claims 2
- 201000000094 Fanconi anemia complementation group R Diseases 0.000 claims 2
- 201000000140 Fanconi anemia complementation group T Diseases 0.000 claims 2
- -1 HELO Proteins 0.000 claims 2
- 101000770953 Homo sapiens DNA repair endonuclease XPF Proteins 0.000 claims 2
- 101000620735 Homo sapiens DNA repair protein RAD51 homolog 1 Proteins 0.000 claims 2
- 101000981336 Homo sapiens Nibrin Proteins 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 101700002522 BARD1 Proteins 0.000 claims 1
- 102100028048 BRCA1-associated RING domain protein 1 Human genes 0.000 claims 1
- 102100035631 Bloom syndrome protein Human genes 0.000 claims 1
- 108091009167 Bloom syndrome protein Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100033832 Crossover junction endonuclease EME1 Human genes 0.000 claims 1
- 102100027041 Crossover junction endonuclease MUS81 Human genes 0.000 claims 1
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 claims 1
- 230000033616 DNA repair Effects 0.000 claims 1
- 102100039116 DNA repair protein RAD50 Human genes 0.000 claims 1
- 102100034483 DNA repair protein RAD51 homolog 4 Human genes 0.000 claims 1
- 102100028285 DNA repair protein REV1 Human genes 0.000 claims 1
- 102100027830 DNA repair protein XRCC2 Human genes 0.000 claims 1
- 102100027829 DNA repair protein XRCC3 Human genes 0.000 claims 1
- 102100034546 E3 ubiquitin-protein ligase FANCL Human genes 0.000 claims 1
- 108010087740 Fanconi Anemia Complementation Group A protein Proteins 0.000 claims 1
- 102000009095 Fanconi Anemia Complementation Group A protein Human genes 0.000 claims 1
- 108010027673 Fanconi Anemia Complementation Group C protein Proteins 0.000 claims 1
- 102000018825 Fanconi Anemia Complementation Group C protein Human genes 0.000 claims 1
- 108010026653 Fanconi Anemia Complementation Group D2 protein Proteins 0.000 claims 1
- 102000013601 Fanconi Anemia Complementation Group D2 protein Human genes 0.000 claims 1
- 108010077898 Fanconi Anemia Complementation Group E protein Proteins 0.000 claims 1
- 102000010634 Fanconi Anemia Complementation Group E protein Human genes 0.000 claims 1
- 108010022012 Fanconi Anemia Complementation Group F protein Proteins 0.000 claims 1
- 102000012216 Fanconi Anemia Complementation Group F protein Human genes 0.000 claims 1
- 108010033305 Fanconi Anemia Complementation Group G protein Proteins 0.000 claims 1
- 102000007122 Fanconi Anemia Complementation Group G protein Human genes 0.000 claims 1
- 108700026162 Fanconi Anemia Complementation Group L protein Proteins 0.000 claims 1
- 102100027285 Fanconi anemia group B protein Human genes 0.000 claims 1
- 102100034554 Fanconi anemia group I protein Human genes 0.000 claims 1
- 102100034552 Fanconi anemia group M protein Human genes 0.000 claims 1
- 102100027284 Fanconi-associated nuclease 1 Human genes 0.000 claims 1
- 101000785776 Homo sapiens Artemin Proteins 0.000 claims 1
- 101000934870 Homo sapiens Breast cancer type 1 susceptibility protein Proteins 0.000 claims 1
- 101000925818 Homo sapiens Crossover junction endonuclease EME1 Proteins 0.000 claims 1
- 101000982890 Homo sapiens Crossover junction endonuclease MUS81 Proteins 0.000 claims 1
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 claims 1
- 101000743929 Homo sapiens DNA repair protein RAD50 Proteins 0.000 claims 1
- 101001132266 Homo sapiens DNA repair protein RAD51 homolog 4 Proteins 0.000 claims 1
- 101000649306 Homo sapiens DNA repair protein XRCC2 Proteins 0.000 claims 1
- 101100119754 Homo sapiens FANCL gene Proteins 0.000 claims 1
- 101000914679 Homo sapiens Fanconi anemia group B protein Proteins 0.000 claims 1
- 101000848174 Homo sapiens Fanconi anemia group I protein Proteins 0.000 claims 1
- 101000848187 Homo sapiens Fanconi anemia group M protein Proteins 0.000 claims 1
- 101000914689 Homo sapiens Fanconi-associated nuclease 1 Proteins 0.000 claims 1
- 101000582631 Homo sapiens Menin Proteins 0.000 claims 1
- 101001128138 Homo sapiens NACHT, LRR and PYD domains-containing protein 2 Proteins 0.000 claims 1
- 101000894871 Homo sapiens Transcription regulator protein BACH1 Proteins 0.000 claims 1
- 101000607909 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 1 Proteins 0.000 claims 1
- 101000814276 Homo sapiens WD repeat-containing protein 48 Proteins 0.000 claims 1
- 102100030550 Menin Human genes 0.000 claims 1
- 102100031897 NACHT, LRR and PYD domains-containing protein 2 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100024403 Nibrin Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102000001195 RAD51 Human genes 0.000 claims 1
- 108010068097 Rad51 Recombinase Proteins 0.000 claims 1
- 101000770949 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) 3'-flap repair endonuclease Xpf Proteins 0.000 claims 1
- 102100039865 Ubiquitin carboxyl-terminal hydrolase 1 Human genes 0.000 claims 1
- 102100039414 WD repeat-containing protein 48 Human genes 0.000 claims 1
- 108010074310 X-ray repair cross complementing protein 3 Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000011476 stem cell transplantation Methods 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 108010073629 xeroderma pigmentosum group F protein Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263880P | 2015-12-07 | 2015-12-07 | |
| PCT/US2016/065079 WO2017100162A1 (en) | 2015-12-07 | 2016-12-06 | Combination for the effective treatment of metastatic cancer in patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3386546T3 true FI3386546T3 (fi) | 2024-12-05 |
Family
ID=57708742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP16820404.8T FI3386546T3 (fi) | 2015-12-07 | 2016-12-06 | Yhdistelmä metastaattisen syövän tehokkaaseen hoitoon potilailla |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11154520B2 (enExample) |
| EP (1) | EP3386546B1 (enExample) |
| JP (3) | JP6831853B2 (enExample) |
| KR (1) | KR20180086257A (enExample) |
| AU (2) | AU2016367112B2 (enExample) |
| CA (1) | CA3044959C (enExample) |
| DK (1) | DK3386546T3 (enExample) |
| ES (1) | ES2994931T3 (enExample) |
| FI (1) | FI3386546T3 (enExample) |
| HU (1) | HUE069668T2 (enExample) |
| IL (2) | IL290251B2 (enExample) |
| PL (1) | PL3386546T3 (enExample) |
| PT (1) | PT3386546T (enExample) |
| WO (1) | WO2017100162A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150265641A1 (en) | 2012-10-22 | 2015-09-24 | Arnold Glazier | Methods for the Effective Treatment of Metastatic Cancer |
| WO2017214140A1 (en) * | 2016-06-06 | 2017-12-14 | University Of Iowa Research Foundation | Compositions and methods for cancer therapy |
| US12310986B2 (en) | 2018-08-21 | 2025-05-27 | Board Of Regents, The University Of Texas System | Compositions and methods for the treatment of cancer cells by induction of cytotoxic oxidative stress |
| CN114904011B (zh) * | 2021-07-06 | 2023-10-13 | 中国科学院上海硅酸盐研究所 | 非铁基谷胱甘肽消耗协同活性氧物种增强复合材料及其制备方法和应用 |
| EP4376822A4 (en) * | 2021-07-29 | 2025-09-17 | Lantern Pharma Inc | TREATMENT OF CANCER WITH COMBINATIONS OF PARP INHIBITORS AND ACYLFULVENS |
| CN116407557A (zh) * | 2023-05-29 | 2023-07-11 | 四川大学华西医院 | 一种防治出血性脑卒中的药物组合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1305873C (en) * | 1987-05-26 | 1992-08-04 | Howel Gwynne Giles | Method and means for detecting alcohol levels in humans |
| US5639787A (en) | 1995-02-28 | 1997-06-17 | The Center For The Improvement Of Human Functioning Int'l, Inc. | Therapeutic method for the treatment of cancer |
| WO2000076556A2 (en) | 1999-06-11 | 2000-12-21 | Neorx Corporation | High dose radionuclide complexes for bone marrow suppression |
| WO2002002093A2 (en) * | 2000-06-30 | 2002-01-10 | Eli Lilly And Company | Combination containing an antifolate and methylmalonic acid lowering agent |
| AU2003221517B2 (en) | 2002-03-22 | 2010-02-18 | Christian Straka | Cytocapacity test |
| WO2004043374A2 (en) | 2002-11-06 | 2004-05-27 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for treating cancer using proteasome inhibitors |
| US20090123447A1 (en) * | 2007-11-14 | 2009-05-14 | The Regents Of The University Of California | Compositions and methods to inhibit rna viral reproduction |
| WO2011011317A1 (en) * | 2009-07-20 | 2011-01-27 | Summa Health System | Vitamin c and vitamin k, and compositions thereof for treatment of osteolysis or prolongation of prosthetic implant |
| US20150265641A1 (en) * | 2012-10-22 | 2015-09-24 | Arnold Glazier | Methods for the Effective Treatment of Metastatic Cancer |
-
2016
- 2016-12-06 DK DK16820404.8T patent/DK3386546T3/da active
- 2016-12-06 PL PL16820404.8T patent/PL3386546T3/pl unknown
- 2016-12-06 WO PCT/US2016/065079 patent/WO2017100162A1/en not_active Ceased
- 2016-12-06 ES ES16820404T patent/ES2994931T3/es active Active
- 2016-12-06 AU AU2016367112A patent/AU2016367112B2/en active Active
- 2016-12-06 IL IL290251A patent/IL290251B2/en unknown
- 2016-12-06 KR KR1020187019041A patent/KR20180086257A/ko not_active Ceased
- 2016-12-06 JP JP2018549135A patent/JP6831853B2/ja active Active
- 2016-12-06 US US15/778,796 patent/US11154520B2/en active Active
- 2016-12-06 EP EP16820404.8A patent/EP3386546B1/en active Active
- 2016-12-06 FI FIEP16820404.8T patent/FI3386546T3/fi active
- 2016-12-06 CA CA3044959A patent/CA3044959C/en active Active
- 2016-12-06 HU HUE16820404A patent/HUE069668T2/hu unknown
- 2016-12-06 PT PT168204048T patent/PT3386546T/pt unknown
- 2016-12-06 IL IL259512A patent/IL259512B2/en unknown
-
2021
- 2021-01-29 JP JP2021013001A patent/JP7144554B2/ja active Active
- 2021-10-13 US US17/500,169 patent/US20220096405A1/en not_active Abandoned
-
2022
- 2022-01-11 AU AU2022200131A patent/AU2022200131A1/en not_active Abandoned
- 2022-09-15 JP JP2022147352A patent/JP2022171816A/ja active Pending
-
2024
- 2024-01-09 US US18/408,066 patent/US20240216308A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021073262A (ja) | 2021-05-13 |
| US20220096405A1 (en) | 2022-03-31 |
| PL3386546T3 (pl) | 2025-01-27 |
| IL259512B1 (en) | 2023-11-01 |
| AU2016367112B2 (en) | 2022-01-13 |
| US20180338935A1 (en) | 2018-11-29 |
| EP3386546A1 (en) | 2018-10-17 |
| IL290251A (en) | 2022-04-01 |
| US20240216308A1 (en) | 2024-07-04 |
| PT3386546T (pt) | 2024-12-09 |
| AU2016367112A1 (en) | 2018-07-12 |
| JP6831853B2 (ja) | 2021-02-17 |
| IL259512A (en) | 2018-07-31 |
| US11154520B2 (en) | 2021-10-26 |
| EP3386546B1 (en) | 2024-09-04 |
| HUE069668T2 (hu) | 2025-04-28 |
| AU2022200131A1 (en) | 2022-02-10 |
| KR20180086257A (ko) | 2018-07-30 |
| JP2022171816A (ja) | 2022-11-11 |
| ES2994931T3 (en) | 2025-02-04 |
| IL290251B2 (en) | 2024-07-01 |
| WO2017100162A1 (en) | 2017-06-15 |
| JP7144554B2 (ja) | 2022-09-29 |
| CA3044959C (en) | 2024-01-09 |
| IL290251B1 (en) | 2024-03-01 |
| CA3044959A1 (en) | 2017-06-15 |
| DK3386546T3 (en) | 2024-11-25 |
| IL259512B2 (en) | 2024-03-01 |
| JP2019501962A (ja) | 2019-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nickoloff et al. | Translational research in radiation-induced DNA damage signaling and repair | |
| Muñoz et al. | DNA replication stress: from molecular mechanisms to human disease | |
| JP2022500435A5 (enExample) | ||
| Powell et al. | Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers | |
| JP2019501962A5 (enExample) | ||
| JP2020516693A5 (enExample) | ||
| JP2017516784A5 (enExample) | ||
| JP2006528618A5 (enExample) | ||
| CN110582581A (zh) | 用于治疗过度增殖性疾病的方法中的atr激酶的抑制剂 | |
| ES2817414T3 (es) | Régimen de terapia y métodos para sensibilizar células de cáncer tratadas con una terapia epigenética frente a inhibidores de PARP en múltiples cánceres | |
| JP2025503385A (ja) | メニン－ｍｌｌエピジェネティック複合体を破壊することによる消化管間質腫瘍（ｇｉｓｔ）の治療的標的化 | |
| Wang et al. | METTL3-mediated STING upregulation and activation in Kupffer cells contribute to radiation-induced liver disease via pyroptosis | |
| Caragher et al. | Radiotherapy and glioma stem cells: searching for chinks in cellular armor | |
| KR20190038622A (ko) | 재발된 및/또는 난치성 고형 종양 및 비-호지킨 림프종의 치료 | |
| IL259512B2 (en) | Combination for the effective treatment of metastatic cancer in patients | |
| Sesink et al. | The AsiDNA™ decoy mimicking DSBs protects the normal tissue from radiation toxicity through a DNA-PK/p53/p21-dependent G1/S arrest | |
| Chalmers | Radioresistant glioma stem cells—therapeutic obstacle or promising target? | |
| US20220323450A1 (en) | Methods and compositions for treating neuroblastoma in a juvenile mammalian body | |
| JP2015510496A5 (enExample) | ||
| Li et al. | NUP98‐p65 complex regulates DNA repair to maintain glioblastoma stem cells | |
| Kim et al. | Emerging Features of DNA Double-Strand Break Repair | |
| Węsierska-Gądek et al. | Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes | |
| EP4626435A1 (en) | Cancer treatments using a prmt5 inhibitor and a mat2a inhibitor | |
| Aziz et al. | Nanotechnology in cancer therapy: targeting the inhibition of key DNA repair pathways | |
| CN106692155A (zh) | 一种靶向于fen1的小分子抑制剂sc13及其衍生物在制备治疗肿瘤药物中的应用 |